- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.02. | GRI Bio, Inc.: GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment | 1 | GlobeNewswire (USA) | ||
| 04.02. | GRI Bio reports FY results | 1 | Seeking Alpha | ||
| 04.02. | GRI Bio reports $8.2 million cash position, extends runway into Q1 2027 | 2 | Investing.com | ||
| 04.02. | GRI Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.02. | GRI Bio, Inc.: GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights | 171 | GlobeNewswire (Europe) | Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations... ► Artikel lesen | |
| 30.01. | GRI Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.01. | GRI Bio reports positive gene expression data for IPF drug candidate | 2 | Investing.com | ||
| 28.01. | GRI Bio, Inc.: GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF | 172 | GlobeNewswire (Europe) | Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio"... ► Artikel lesen | |
| GRI BIO Aktie jetzt für 0€ handeln | |||||
| 28.01. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.01. | GRI Bio, Inc.: GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures | 2 | GlobeNewswire (USA) | ||
| 22.01. | GRI Bio Announces Reverse Stock Split To Regain Minimum Bid Price Nasdaq Compliance | - | RTTNews | ||
| 21.01. | GRI Bio announces 1-for-28 reverse share split | 1 | Seeking Alpha | ||
| 21.01. | GRI Bio: Aktienzusammenlegung im Verhältnis 1:28 soll Verbleib an der Nasdaq sichern | 6 | Investing.com Deutsch | ||
| 21.01. | GRI Bio announces 1-for-28 reverse stock split to regain Nasdaq compliance | 1 | Investing.com | ||
| 21.01. | GRI Bio, Inc.: GRI Bio Announces Reverse Stock Split | 454 | GlobeNewswire (Europe) | GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company")... ► Artikel lesen | |
| 15.01. | GRI Bio: Aktionäre stimmen für Aktienzusammenlegung - Nasdaq-Anforderungen wieder erfüllt | 2 | Investing.com Deutsch | ||
| 15.01. | GRI Bio, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 09.01. | GRI Bio stockt ATM-Kapitalprogramm auf 7,38 Mio. US-Dollar auf | 10 | Investing.com Deutsch | ||
| 08.01. | GRI Bio: Aktie legt nach positiven Phase-2a-Daten für Lungenfibrose-Wirkstoff zu | 2 | Investing.com Deutsch | ||
| 08.01. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,05 | -0,51 % | BioNTech-Konkurrent Moderna: Satter Kurssprung - jetzt noch einsteigen? | Die Aktie von Moderna hat zuletzt erneut kräftigen Rückenwind erhalten. Die Korrektur seit Ende Januar wurde damit nicht nur vollständig wieder ausgeglichen, das Papier konnte sogar auf ein neues Jahreshoch... ► Artikel lesen | |
| EVOTEC | 5,402 | -1,13 % | Shortseller-Positionen aktuell: Evotec, Gerresheimer, HelloFresh, Renk, Hypoport, Symrise, TUI | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AMGEN | 316,00 | -0,74 % | Leerink Partners senkt Amgen-Prognose für Q1 wegen Lagerbestandsabbau | ||
| VIKING THERAPEUTICS | 28,380 | -0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,381 | -2,81 % | Defence Therapeutics Inc.: Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March | Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,393 | +1,55 % | Vom Labor in die Klinik: NurExone sichert die Reproduzierbarkeit seiner Exosomen-Produktion | ||
| ABIVAX | 93,70 | -0,11 % | EQS-News: ABIVAX: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | EQS-News: ABIVAX
/ Key word(s): Study results
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory... ► Artikel lesen | |
| IBIO | 2,220 | -1,77 % | Jones Trading initiates iBio stock with buy rating on obesity platform | ||
| ARROWHEAD PHARMACEUTICALS | 51,30 | -0,54 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,326 | -0,89 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CYBIN | 4,600 | +1,77 % | Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder | Statistically significant (pDurable effects sustained through at least 6 monthsIn Phase 1 trial most participants were ready for discharge within 3 hours1; Acute effects lasted ~90 minutesGenerally... ► Artikel lesen | |
| CAPRICOR | 24,250 | +0,83 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| OPGEN | 1,568 | 0,00 % | OpGen rebrands as CapForce, shifts to digital investment banking | ||
| MEREO BIOPHARMA | 0,336 | -2,33 % | XFRA MAH0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 17,428 | +0,75 % | Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts |
GRI BIO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,155 (+6,44 %) liegt der Kurs bei 2,560 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GRI BIO INC finden Sie auf Wallstreet Online.